Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
The small nucleic acid drugs developer has positioned itself as a leader in siRNA therapeutics, boasting one of the world’s largest pipelines of drugs using the technology Key Takeaways: Ribo…
RNA drug developer Ribo Life targets fresh funding channel
The biopharma firm has filed for a Hong Kong IPO after already completing eight financing rounds to support its research into cutting-edge nucleotide drugs Key Takeaways: As a pioneer in…
